There was no difference in the treatment failure in the amikacin group ( @ of @ ; @ % ) compared with piperacillin-tazobactum group ( @ of @ ; @ % ) ( p > @ ) and no difference in the incidence of second infection , fungal sepsis and all-cause mortality at day @ and @ between the two study groups ( p > @ ) .